Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Cyclin-dependent kinase inhibitors (CDKIs) and endocrine therapy (ET) are the corner-stone of systemic therapy for patients with hormone-positive (HR+) HER2-negative metastatic breast cancer (MBC). However, limited data exist regarding rechallenge treatment strategies with CDKIs after limiting toxic...

Full description

Bibliographic Details
Main Authors: Jesús Fuentes-Antrás, Alicia de Luna, Alfonso López de Sá, Alberto Ocaña, José Ángel García-Sáenz, Fernando Moreno
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Breast
Subjects:
Metastatic breast cancer
Luminal
CDK inhibitors
Hypertransaminasemia
Rechallenge
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620301983

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620301983

Similar Items